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MicroAbstract	
We retrospectively analyzed the prognostic impact of Proteasome subunit beta type 1 rs12717 
polymorphism in 211 consecutively diagnosed multiple myeloma cases. Patients carrying the 
variant G allele showed significantly shorter progression free survival. In proteasomes of 
individuals with G/G genotype we found significantly reduced protease activity and lower 
inhibitory capacity of bortezomib on the caspase- and trypsin-like activity. 
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Abstract	
Background: Proteasome subunit beta type 1 (PSMB1) rs12717 polymorphism, an SNP with 
unknown functional effect, was recently reported to influence response to bortezomib based 
therapy in follicular lymphoma. 
Patients and Methods: We retrospectively analyzed the prognostic impact of this 
polymorphism in 211 consecutively diagnosed multiple myeloma cases, and performed in 
vitro experiments to look into its functional consequences. 
Results: On univariate analysis patients carrying the variant G allele showed significantly 
shorter progression free survival (PFS) with a pattern suggestive of a gene dose effect (PFS 
26.4, 22.3, and 16.4 months in C/C, C/G, and G/G patients, respectively, p=0.002). On 
multivariate analysis, carrying the G/G genotype was a significant independent risk factor for 
relapse (HR 2.29, p<0.001) with a similar trend in C/G carriers (HR 1.33, p=0.097) when 
compared to the major allele carrier C/C cohort. Our subsequent in vitro analyses 
demonstrated significantly reduced protease activity in proteasomes of individuals with G/G 
genotype compared to that of C/C carriers, despite the fact that the PSMB1 expression and the 
proteasome assembly remained unaltered. Bortezomib exhibited a lower inhibitory capacity 
on the caspase- and trypsin-like activity of proteasomes from G/G individuals. 
Conclusion: Our results show that carriership of PSMB1 rs12717 minor allele is predictive for 
suboptimal response with bortezomib treatment, which could be explained by less active 
proteasomes which are less sensitive to bortezomib, and myeloma cells consequently relying 
on other escape mechanism to cope with the abundance of misfolded proteins. 
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Introduction	
Proteasome inhibitors (PIs) have a fundamental role in the treatment of multiple 
myeloma (MM). Bortezomib, the first in class PI received accelerated approval from the U.S. 
Food and Drug Administration (FDA) in relapsed refractory MM in 2003, and entered into 
phase 3 trials in first line setting.1-3 Bortezomib based combinations are currently standard 
upfront treatments for MM in most countries, and second generation PIs are increasingly used 
following the FDA and subsequent European Medicines Agency (EMA) approval of 
carfilzomib and ixazomib. 
Proteasomes are multienzyme complexes providing pathway for the degradation of 
poly-ubiquitinated intracellular proteins thereby eliminating misfolded or unfolded proteins, 
as well as key regulators of important cellular processes including cell-cycle progression, 
DNA repair, apoptosis, immune response, signal transduction, transcription, metabolism, and 
developmental programs.4,5 The 26S proteasome, a large 2.4-MDa ATP-dependent proteolytic 
complex located in both the cytoplasm and the nucleus, consists of a 20S core catalytic 
cylindrical complex capped at both ends by 19S regulatory subunits.6 The core structure is 
composed of 4 axially stacked rings of non-identical subunits: 2 alpha rings each composed of 
7 non-identical alpha subunits (α1–7, encoded by PSMA1–7) and 2 beta rings each formed by 
7 non-identical beta subunits (β1–7, encoded by PSMB1–7).7 Three β subunits (β5, β2, and 
β1) are located on the inner surface of the proteolytic chamber and are responsible for 
chymotrypsin-like, trypsin-like, and post-glutamyl peptide hydrolyzing (caspase-like) 
activities, respectively.8 Other β subunits are essential for the formation and stability of the 
proteolytic environment on the inner surface of the heptameric rings. The exact role of these 
subunits however, is yet to be characterized. It has also been reported that PSMB1 (coding for 
β6 subunit) has a potential role as transcriptional activator.9,10 
High proteasome activity has been reported in different malignancies.11 In malignant 
plasma cells, that exhibit extremely active protein synthesis, proteasomes along with 
chaperones, such as heat shock proteins, play critical role in cellular homeostasis. This might 
explain the therapeutic window of PI treatment in MM and the additional effect of heat shock 
protein inhibitors combined with PIs.12 Bortezomib binds to the β5 subunit, but also interacts 
with other subunits of proteasome, such as the β1 subunit.13 Some of the new generation PIs, 
such as marizomib, inhibits all three proteolytic activities. Although PSMB5 variants have 
been identified previously in preclinical models of bortezomib resistance, they were not 
detected in relapsed/refractory patients’ tumor samples, suggesting alternative mechanisms 
behind bortezomib resistance.14 
Proteasome subunit beta type 1 (PSMB1) rs12717 single nucleotide polymorphism 
(c.31C>G substitution resulting in p.Pro11Ala amino acid change) was recently reported to be 
associated with greater clinical benefit in relapsed follicular lymphoma patients treated with 
bortezomib-containing combination.15 Our hypothesis was that PSMB1 P11A polymorphism 
could affect the function of proteasomes and therefore have an impact on the prognosis of 
myeloma, especially in patients treated with PI based regiments. To the best of our knowledge 
the functional consequence of PSMB1 P11A polymorphism has not been tested in MM, apart 
from one single study with limited number of patients showing no statistically significant 
association between genotype and survival.14 
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Patients	and	Methods	
Patients,	clinical	data,	treatment,	and	response	criteria	
We analyzed the association of PSMB1 P11A polymorphism and treatment outcome of 
211 consecutively diagnosed myeloma patients having had first line chemotherapy at the St. 
Laszlo Hospital, Budapest, Hungary between January 2007 and November 2013. ISS and 
FISH status were established at diagnosis, FISH testing was performed on bone marrow slides 
using probes for chromosome 13q and 17p deletion, translocation (11;14), (4;14), (14;16), and 
1q amplification. FISH results were available in 194 out of the 211 patients. For the purpose 
of this study, patients with t(4;14), t(14;16), 1q amplification, and del(17p) were grouped 
together as high risk. Previous studies have shown that del(13q) in patients lacking t(4;14) and 
del(17p) was no longer of prognostic significance.16,17  
The treatment decision was the discretion of the treating physician; treatment continued 
until best response and then the transplant eligible patients received a high dose 
cyclophosphamide-primed stem cell mobilization, followed by high-dose melphalan 
conditioned ASCT. Response [complete response (CR), very good partial response (VGPR), 
partial response (PR) no response (NR) and progressive disease (PD)], and survival measures 
[progression free survival (PFS) and overall survival (OS)] and relapse criteria were defined 
according to published guidelines.18 Response was formally assessed at the end of the 
treatment, or following transplant in case of ASCT patients. During their follow up, patients 
were reviewed regularly every 2-3 months until disease progression or death. The median 
follow up was 40 months. 
The study was approved by the Hungarian National Ethics Committee, and participants 
signed informed consents. 
Genotyping	
Genomic DNA was isolated from bone marrow or peripheral blood. PSMB1 P11A 
polymorphism was tested using LightCycler 480II (Roche Diagnostics, Basel, Switzerland) 
melting curve analysis. Amplification primers (PSMB1-LCF: 5’- GTG AGA CAG CAA GTG 
TCG -3’ and PSMB1-LCR: 5’- GTG ACT CCT AAA TAG GCT TCA G -3’) and 
hybridization probes (PSMB1-SENS: 5’- GGC TCC TGG CAG AGA CTT GG – Fluorescein 
and PSMB1-ANC: 5’ - Cy5- ATG GAA CCG CAC AGA GCC G - Phosphate) were 
designed by LightCycler Probe Design software (Roche Diagnostics, Basel, Switzerland). 
Asymmetric polymerase chain reaction with shifted forward (0.15 M) and reverse primer 
(0.5 M) concentrations was performed with the addition of 25 ng genomic DNA, and 
labelled oligonucleotides (0.25 M each) with MyTaqTM Mix (Bioline, Bio-25042, Taunton, 
USA) according to the manufacturers’ instructions. Cycling conditions were as follows: initial 
denaturation at 95oC for 3 min, 70 cycles of 95oC denaturation, 50oC annealing, and 72oC 
extension, melting curve analysis from 40oC to 80oC. 
Flow	cytometry	analysis	of	proteasomes	and	PSMB1	expression	
For in vitro characterization of proteasome expression and function, healthy volunteers 
previously genotyped as either PSMB1 major variant C/C or homozygous G/G minor variant 
(3 males and four females, mean age: 42±8 years) were investigated. EDTA anticoagulated 
whole blood samples were fixed with 1% paraformaldehyde (37˚C, 5 min), spun down (500g, 
5 min), washed with PBS, and sonicated (10 sec, 37 kHz, 50/100W). The cells were 
resuspended in PBS and labelled with rabbit polyclonal anti-PSMB1 (1:80, Biomol, 
Hamburg, Germany) or anti-proteasome 20S alpha + beta (1:100, Abcam, Cambridge, UK) 
antibodies along with cell type-specific markers, such as phycoerythrin (PE) conjugated anti-
CD3 (1:200), PE-conjugated anti-CD14 (1:100), or Peridinin Chlorophyll Protein Complex 
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(PerCP) conjugated anti-CD19 (1:100) antibodies (40 min, 37°C). After washing, the cells 
were subjected to Alexa Fluor 488-conjugated goat anti-rabbit IgG (H+L) (1:100, Life 
Technologies, 30 min, 37oC), washed, and resuspended in PBS containing 2.5 μM DRAQ5 
(Biostatus, Shepshed, UK). To avoid optical interference, DRAQ5 staining was omitted, when 
PerCP-conjugated marker was used. The cells were analyzed by a FACSCanto II flow 
cytometer at 488 nm and 633 excitations (emission filters: 488/10, 585/42, 670LP, and 660/20 
nm). Sequential gating was applied, where nucleated cells were first selected on the basis of 
DRAQ5 staining (with the exception of anti-CD19 staining), then forward scatter and side 
scatter parameters were used for further gating. T-cells, B-cells, and monocytes were 
identified on the basis of CD3, CD19, and CD14 labeling, respectively, whereas granulocytes 
were identified solely on the basis of scatter parameters. Relative anti-PSMB1 and anti-
proteasome 20S labeling was expressed by the median fluorescence intensities divided by the 
median values obtained with the secondary antibodies only (autofluorescence control). 
Assessment	of	proteasome	functions	
For studying proteasome function, peripheral blood mononuclear cells (PBMC) were 
isolated by density gradient separation (1200g, 20 min, Leucoprep Lymphocyte Separation 
Media, Intron Biotechnology, South-Korea), washed 3 times with saline solution, and lysed 
with a buffer containing 40mM Tris, 50mM NaCl, 5mM MgCl2, 2mM β-mercaptoethanol, 
10% glycerol. After sonication and removal of cell debris, the total protein concentration was 
assessed by Bradford assay, and adjusted to 2.5 mg/ml. The chymotrypsin-like, caspase-like, 
and trypsin-like activities of the lysates were determined by Proteasome Activity Fluorometric 
Assay Kit II (UBPBio) according to the manufacturers’ instructions. Briefly, 120 µl assay 
buffer containing the fluorogenic peptide substrate was added to 30 µl of the lysates. For 
studying bortezomib inhibition, the samples were preincubated with the drug (room 
temperature, 30 min) prior to the start of the reaction. The generation of fluorescent product 
(460 nm) was assessed by a fluorescence plate reader at 360 nm excitation. The specific 
activities were calculated from the initial slopes of the kinetic curves and the protein content 
of the samples. 
Statistical	methods	
Comparisons of dichotomous variables were performed by Pearson’s chi-square test or 
Fisher’s exact test as appropriate; continuous variables were compared with Kruskal-Wallis or 
Mann-Whitney tests. Log-rank test was performed to compare PFS and OS. Following 
univariate analysis, variables with p values <0.05 in the entire cohort were included in the 
multivariate analysis. Using the stepwise selection procedure for all of the variables of interest 
(sex, age, ISS, FISH, ASCT, bortezomib treatment, immunoglobulin, LDH) the Cox 
proportional hazard model was used for multivariate analysis of OS and PFS. The few 
missing ISS and FISH value were replaced using random imputation. Adjusted hazard ratios 
(HR), 95% confidence intervals (CI) values, and tests for interaction were computed. For the 
comparison of PSMB1 expression, proteasome assembly, and function in the different 
subgroups, Student’s t test was used after testing for the normality and homogeneity of 
variances. P < 0.05 was considered as significant difference. The analyses were carried out 
using the SPSS (version 20.0 SPSS, Chicago, IL, USA) software package. 
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Results 
Study	population	
Patient characteristics are shown in Table 1. Among the 211 newly diagnosed 
consecutive MM patients 105 were males and 106 females, the median age was 64 (28–84) 
year. The majority of them had either IgG (57.3%) or IgA (19.9%) myeloma, 21.8% had light 
chain and 0.9% non-secretory disease. ISS was calculated in each case at diagnosis, with 25.8, 
24.4, and 49.8% of the patients being in ISS groups 1, 2, and 3, respectively. As the clinical 
behavior of the ISS 1 and 2 groups was similar, these two cohorts were merged. According to 
our pre-defined FISH risk stratification, 31.4% of the patients were allocated into the high risk 
and 68.6% into the low risk group. 
154 patients [77 males and 77 females; median age: 61.5 (28–84) years] received 
bortezomib based treatment and 57 [28 males and 29 females; median age: 68 (48–84) years, 
p for age <0.001] had other, non-bortezomib-containing protocols. 
Within the bortezomib-treated group, 83 transplant eligible patients were treated with 
bortezomib-thalidomide-dexamethasone (VTD)19, while melphalan-prednisolon-bortezomib 
(MPV)20, the standard therapy for older patients, was applied in 45 cases. 20 other patients 
had bortezomib-doxorubicin-dexamethasone (PAD)21 and 6 bortezomib-dexamethasone 
(VD)2 chemotherapy. Other, non-bortezomib-containing protocols were applied as follows: 
cyclophosphamide-thalidomide-dexamethasone22, vincristin-doxorubicin-dexamethasone 
(VAD)23, lenalidomide-dexamethasone24, and melphalan-prednisolon (MP) the numbers and 
genotype distribution in these subcohorts are summarized in table 1. 
59.1% of the bortezomib-treated patients had first line ASCT, whereas the ASCT 
frequency was lower, 35.1% in the non-bortezomib group reflecting the fact that from 2007 in 
our center VTD became the preferred induction in transplant candidates, while oral protocols 
remained more feasible for frailer patients. The median age of the first line transplanted and 
non-first line transplanted patients was 58 (range: 28–70) and 72 (range: 39–84) years, 
respectively (p<0.001). There was no significant difference in the distribution of disease 
characteristics, prognostic markers, and applied treatment between the various PSMB1 
genotype groups (Table 1). 
PSMB1	allele	frequencies	
Genotype distribution in our patient cohort was as follows: 84 patients (39.8%) had 
homozygous C/C, 95 patients (45%) heterozygous C/G and 32 patients (15.2%) G/G 
genotype, similar to that published previously.14 The minor allele frequency (37.7±4.7%) in 
MM patients was not different from the reported allele frequency for Caucasian reference 
population (40.4±7.0%) in the 1000 Genome Project or (34.8-46.0%) in the National Center 
for Biotechnology Information (NCBI) dbSNP databases.25  
PSMB1	genotype	and	response	to	treatment	
4 patients had no disease reassessment because of early death. Within the whole cohort, 
41.2, 19.4, and 30.8% of the patients had CR, VGPR, and PR, respectively, and 6.6% 
exhibited NR. Slightly more patient entered into CR in the C/C genotype group (48.8%) as 
compared to the G/C and G/G groups (35.8 and 37.5%, respectively), but this difference was 
not significant (p=0.189) Apart from this, there were no associations between the response 
levels and the genotype groups neither in the whole cohort, nor in subgroups according to ISS, 
FISH or chemotherapy type (data not shown). 
There was no difference between the numbers of chemotherapy cycles required to reach 
the best response in the three genotype subgroups. Approximately half of the patients had 
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ASCT consolidation, and the proportion of patients having ASCT was not different between 
the three genotype groups. 
PSMB1	genotype	and	univariate	analysis	of	survival	
The median PFS and OS of the whole group were 23.4 (20.7-26.1) and 55.7 (49.6-61.8) 
months, respectively. The known predictors (age, ASCT, ISS, FISH) all had significant 
impacts on survival.  
Analyzing the three PSMB1 genotype groups the PFS was 26.4 (22.4-30.4), 22.3 (18.3-
26.4), and 16.4 (10.2-22.6) months (p=0.002), and the OS 58.5 (53.5-63.4), 47.7 (34.8-60.6), 
and 64.4 (42.1-86.7) months (p=0.27) in C/C, C/G and G/G patients, respectively (Figure 1). 
In Cox proportional hazard modeling, carrying two G alleles increased the chance of relapse 
by 2.14 (1.39-3.29; p=0.001) with a trend in carriers of one single G allele [HR 1.36 (0.98-
1.89), p=0.067], while no statistically significant difference was seen in the OS of the 
subgroups. 
PSMB1	genotype	and	multivariate	analysis	of	survival	
In multivariate analysis, besides age, ISS, FISH, bortezomib treatment and ASCT, G/G 
genotype was also a significant risk factor for shorter PFS. Homozygous G/G patients had a 
shorter PFS compared to C/C genotype patients with a hazard ratio of 2.29 (1.46–1.36) 
(p<0.001) (Table 2), whereas heterozygous C/G patients showed a trend of worse prognosis 
with a hazard ratio of 1.33 (0.95–1.86) (p=0.097). Regarding OS, a significant difference 
between the C/C and C/G genotypes was found, but not in the comparison of the C/C and G/G 
genotypes (Table 2). 
Statistical interaction testing did not show significant interactions of PSMB1 genotype 
and either bortezomib treatment (p=0.092 for G/G vs C/C, and p=0.63 for C/G vs C/C 
regarding PFS) or ASCT (p=0.420), however, revealed interaction of PSMB1 with FISH risk 
status regarding PFS (p=0.044) and with ISS regarding OS (p=0.022).  
Subgroup	analyses	
In the PFS and OS of the ISS and FISH stratified subgroups, we found the same pattern 
as in the whole study population with significant differences between the C/C, C/G and G/G 
genotype groups both in the ISS 1&2 and the ISS 3 and standard risk FISH subgroups, but not 
in the FISH high risk group (Table 3). 
The PSMB1 genotype mattered the most in bortezomib-treated patients, where it has a 
highly significant effect in the bortezomib-treated cohort (Figure 1/B and Table 3). 
Assessment	of	functional	consequence	of	the	PSMB1	polymorphism	
To investigate the possible molecular mechanism how P11A (c.31C>G) polymorphism 
in PSMB1 may influence the proteasome assembly and/or function, first the amount of 
proteasomes (Figure 2A) and the expression level of PSMB1 (Figure 2B) were determined in  
peripheral white blood cells obtained from healthy individuals with C/C or G/G genotype. No 
difference between the two subgroups was found in proteasome levels or PSMB1 expression 
(Figure 2A-B). Similarly, no difference was observed when these two parameters were 
assessed specifically in various types of nucleated peripheral blood cell types, i.e., monocytes, 
T-cells, B-cells, and granulocytes (Figure 2A-B). 
Following this, the protease activities of proteasomes of C/C and G/G genotype carrier 
subgroups were analyzed and found that chymotrypsin-, trypsin- and caspase-like activities 
were all significantly lower in the G/G subgroup, indicating selective reduction of the 
proteasome function in individuals carrying the G/G polymorphism (Figure 2C). 
We also studied the in vitro inhibitory effect of bortezomib on the chymotrypsin-, 
trypsin- and caspase-like activities of the proteasomes, and found a three-fold difference 
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between the IC50 values of bortezomib inhibition of the caspase-like activity of proteasomes 
of healthy subjects with G/G and C/C genotypes (2.05 vs 6.07 µM). More profound 
difference, one order of magnitude shift was seen in the IC50 values, when the trypsin-like 
activities were blocked by bortezomib (44.4 vs. 462 µM) (Figure 2D). 
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Discussion	
Our results confirm that PSMB1 P11A polymorphism has a significant impact on the 
survival of myeloma patients. We originally hypothesized that this polymorphism might 
interact with bortezomib treatment, given its mechanism of action, but we could not 
demonstrate statistical interaction between bortezomib exposure and PSMB1 genotype; 
however, this could be the result of the smaller number of patients in the non-bortezomib 
treated group.  
The literature of PSMB1 P11A polymorphism is sparse. A study compared the outcome 
of relapsed follicular lymphoma patients treated with rituximab in combination with or 
without bortezomib. It was reported that one biomarker pair, i.e., PSMB1 P11A G allele 
carriers with low CD68 expression, was associated with a significant PFS benefit, when these 
patients were treated with the combination of bortezomib and rituximab as compared to those 
having received rituximab as monotherapy.15  
Another study analyzed the sequence of β-subunit genes of the 20S proteasome in 
patients with relapsed multiple myeloma using samples from patients who participated in the 
phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of 
bortezomib versus high-dose dexamethasone. No statistically significant interaction between 
the PSMB1 P11A and time-to-progression or OS was found; however, this particular sub-
analysis included only 23 patients and still, there was a marginal association (p=0.077). This 
report concluded that because of the limited size of their dataset, additional studies are 
required to further evaluate this SNP in MM.14 
In Cox modeling of PFS, the risk of relapse increased in the presence of one G allele 
and then increased further with the second, which finding could suggest the presence of a 
gene dose effect; however, currently there is no published data on the functional consequence 
of the PSMB1 P11A polymorphism. Therefore, we investigated whether this polymorphism 
influences the assembly, the functions and the inhibitability of proteasomes using peripheral 
blood cells of healthy individuals. In addition to the fact that the availability of plasma cell of 
MM patients is rather limited, these cells most likely carry a high number of somatic 
mutations, which can cause such a statistical noise, that may hamper the analysis of 
proteasome activities. Alternatively, myeloma cell lines could be used. However, cell line 
pairs with the same genetic background possessing G/G or C/C genotype for the PSMB1 gene 
are not available thus far. 
The protein encoded by PSMB1 is the β6 subunit, one of the two times seven elements 
of the inner proteolytic chamber of the proteasome. This subunit has no known direct 
proteolytic activity, but has been proposed to contribute to the assembly and stability of the 
two heptameric beta rings of proteasomes, establishing the proteolytic environment on their 
inner surface. Our findings, that proteasomes with G/G PSMB1 genotype exhibit lower 
peptidase activities and lower sensitivity to bortezomib in terms of the caspase-like and 
trypsin-like activities, are in line with this proposed model, and suggest an indirect interaction 
with the proteasome function. Our experiments clearly demonstrated that this polymorphism 
is not neutral; however, further studies are required to elucidate the exact molecular 
mechanism how the polymorphism in PSMB1 leads to reduced activity and changes in 
bortezomib-sensitivity of proteasomes. Nevertheless, we can speculate, that to maintain 
appropriate cellular homeostasis, these cells compensate for the reduced proteasome 
proteolytic activities with increased activities in the alternative degradative mechanisms, 
which ultimately may lead to reduced susceptibility to proteasome inhibition as observed in 
cells homozygous for P11A polymorphism (Figure 2D). This concept may especially apply to 
cell types with intense protein synthesis and secretion, e.g., plasma cells, where the 
proteolytic burden is grossly increased. Bortezomib is thought to drive cells to programmed 
cell death by inhibiting the proteasomal degradation of unfolded proteins thereby 
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overwhelming the degradation capacity of the cell and triggering the unfolded protein 
response.26,27 This may help explain why bortezomib has an apparent potentiating effect when 
given as co-therapy with 17-AAG, a heat shock protein 90 inhibitor in patients with relapsed 
or refractory MM.12 
As regards to another component of the proteasome complex, namely PSMA5 it has 
been reported that low plasma levels are associated with longer PFS in mantle cell lymphoma 
treated with bortezomib.28 In addition, recent data showed that silencing individual 
proteasome genes including PSMA5 and PSMB2/3/7 sensitized multiple myeloma cells to 
bortezomib.29,30 However, similar data in connection with PSMB1 is not reported thus far. 
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Conclusion	
PSMB1 P11A is a novel predictive marker in multiple myeloma, which could help to 
identify patients with a probability of having a suboptimal response to bortezomib who might 
benefit from alternative management, which could potentially include the inhibition of heat 
shock proteins. 
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Clinical	Practice	Points	
 PSMB1 P11A polymorphism results in decreased protease activity of proteasomes and 
reduced inhibitory effect of bortezomib on their activity. 
 Myeloma patients carrying the variant allele of the PSMB1 P11A polymorphism have 
a significantly shorter progression free survival. 
 Based on this PSMB1 P11A is a new predictive marker which could help to identify 
patients who could benefit from alternative management. 
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Table 1. Patients’ Characteristics 
 
  PSMB1 P11A  
 All C/C C/G G/G p 
n (%) 211 84 (39.8%) 95 (45.0%) 32 (15.2%)  
Sex Male 105 (49.8%) 42 (50%) 49 (51.6%) 14 (43.8%) 0.745 
 Female 106 (50.2%)  42 (50%) 46 (48.4%) 18 (56.2%)  
Age (years) 64 (28–84) 63 (28–84) 64 (32–84) 65.5 (49–84) 0.306 
ISS 1&2 105 (50.2) 38 (45.8) 52 (55.3) 15 (46.9) 0.419 
 3 104 (49.8) 45 (54.2) 42 (44.7) 17 (53.1)  
FISH  SR 133 (68.6) 50 (64.9) 57 (65.5) 26 (86.7) 0.067 
 HR 61 (31.4) 27 (35.1) 30 (34.5) 4 (13.3)  
LDH normal 158 (80.2) 69 (86.2) 65 (74.7) 24 (80.0) 0.174 
 high 39 (19.8) 11 (13.8) 22 (25.3) 6 (20.0)  
Bortezomib No 57 (27.0) 16 (19.0) 28 (29.5) 13 (40.6) 0.050 
 Yes 154 (73.0) 68 (81.0) 67 (70.5) 19 (59.4)  
Treatment VTD 83 (39.3) 33 (39.3) 39 (41.1) 11 (34.4) 0.800 
 PAD 20 (9.5) 11 (13.1) 6 (6.3) 3 (9.4) 0.303 
 MPV 45 (21.3) 21 (25.0) 20 (21.1) 4 (12.5) 0.339 
 VD 6 (2.8) 3 (3.6) 2 (2.1) 1 (3.1) 0.836 
 Thal 36 (17.1) 10 (11.9) 17 (17.9) 9 (28.1) 0.111 
 Len 3 (1.4) 1 (1.2) 2 (2.1) 0 (0.0) 0.667 
 VAD 8 (3.8) 2 (2.4) 5 (5.3) 1 (3.1) 0.588 
 MP 10 (4.7) 3 (3.6) 4 (4.2) 3 (9.4) 0.399 
ASCT No 100 (47.4) 39 (46.4) 43 (45.3) 18 (56.2) 0.546 
 Yes 111 (52.6) 45 (53.6) 52 (54.7) 14 (43.8)  
      
 
FISH high risk: t(4;14), t(14;16), 1q amplification and deletion 17p; standard risk: all others. 
 
Abbreviations: ASCT, autologous stem cell transplantation; FISH, fluorescence in situ 
hybridization; HR, high risk; ISS, International scoring system; MPV, melphalan, 
prednisolon, bortezomib; PAD, bortezomib, doxorubicin, dexamethasone; SR, standard risk; 
VAD, vincristin, doxorubicin, dexamethasone; VTD, bortezomib, thalidomide, 
dexamethasone  
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Table 2. Multivariate analysis of PFS and OS 
 
 
Abbreviations: ASCT, autologous stem cell transplantation;  CI, confidence interval; FISH, 
fluorescence in situ hybridization; HR, hazard ratio; ISS, International scoring system; OS, 
overall survival; PFS, progression free survival 
  
 PFS    OS    
 HR CI95  p HR CI95  p 
Age 1.005 0.987 1.024 0.554 0.998 0.976 1.021 0.872 
ISS 1.360 1.120 1.652 0.002 1.904 1.466 2.473 <0.001 
FISH 1.647 1.178 2.303 0.004 1.606 1.076 2.396 0.020 
Bortezomib 1.013 0.711 1.444 0.942 0.998 0.644 1.546 0.991 
ASCT 0.518 0.353 0.761 0.001 0.479 0.295 0.776 0.003 
PSMB    0.002    0.041 
PSMB C/G vs C/C 1.327 0.950 1.855 0.097 1.718 1.122 2.629 0.013 
PSMB G/G vs C/C 2.293 1.458 3.604 <0.001 1.570 0.876 2.811 0.129 
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Table 3. Subgroup analysis of PFS and OS 
 
  PSMB1 P11A  
  C/C C/G G/G p 
PFS ISS 1&2 38.0 (13.4-62.6) 25.5 (19.2-31.8) 26.8 (17.7-35.9) 0.04 
  3 24.9 (19.1-30.7) 18.2 (7.8-28.6) 9.4 (4.9-13.8) 0.005 
 FISH  SR 34.4 (28.0-40.1) 24.2 (20.5-27.9) 16.4 (7.5-25.3) <0.001 
  HR 18.2 (10.6-25.8) 18.2 (12.6-23.8) 21.0 (12.1-29.9) 0.356 
 Bortezomib No 22.5 (15.2-29.8) 19.3 (16.7-21.9) 17.3 (6.6-27.9) 0.387 
  Yes 26.4 (20.1-32.6) 24.2 (20.4-28.0) 16.4 (6.3-26.5) 0.006 
 ASCT No 15.4 (12.7-18.1) 15.3 (6.4-24.2) 12.2 (3.7-20.7) 0.310 
  Yes 34.6 (29.1-40.1) 27.4 (22.4-32.4) 21.3 (13.2-29.4) 0.006 
OS ISS 1&2 NR 87.1 (47.6-126.6) NR 0.391 
  3 52.4 (39.5-65.3) 29.2 (14.6-43.8) 21.8 (0-51.1) 0.012 
 FISH  SR NR 52.3 (39.7-64.9) 64.4 (28.5-100.3) 0.038 
  HR 43.2 (27.6-58.8) 41.3 (25.1-57.5) 50.0 (0-105.9) 0.513 
 Bortezomib No 58.5 (56.1-60.8) 39.5 (12.7-66.3) 65.1 (19.9-110.3) 0.597 
  Yes NR 47.7 (31.7-63.6) 55.1 (23.5-86.6) 0.306 
 ASCT No 40.2 (25.7-54.6) 25.1 (9.3-40.9) 64.4 (0.0-139.3) 0.541 
  Yes 79.2 56.0 (20.2-91.8) 55.1 (23.1-87.1) 0.331 
 
Abbreviations: ASCT, autologous stem cell transplantation;  CI, confidence interval; FISH, 
fluorescence in situ hybridization; HR, high risk; ISS, International scoring system; NR, not 
reached; OS, overall survival; PFS, progression free survival; SR, standard risk 
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Legends	to	Figures	
Figure 1. Effect of PSMB1 P11A (c.31G>C) polymorphism on progression free survival 
(PFS) of multiple myeloma patients, (A) the whole group, and (B) the bortezomib 
treated patients  
Patients with G/G genotype have significantly shorter PFS compared to those with 
homozygous C/C while in case of G/C patients there is a similar trend suggesting a gene-dose 
effect. 
 
Abbreviations: HR, hazard ratio; CI confidence interval 
 
Figure 2. Effect of PSMB1 P11A (c.31G>C) polymorphism on the PSMB1 expression, 
proteasome assembly and function. The amount 20S proteasomes (A) and the expression of 
PSMB1 (B) were compared in various white blood cell types of healthy individuals with C/C 
or G/G genotype. (C) The different peptidase activities of proteasomes were assessed in 
peripheral blood cells of subjects homozygous for the studied polymorphism. (D) The relative 
inhibitory effect of bortezomib on proteasome peptidase activities was determined. Despite 
that the PSMB1 expression and proteasome assembly did not differ between the two genetic 
groups, subjects with G/G genotypes exhibited significantly lower proteosomal activities (n=4 
each, p<0.05). Trypsin-like and caspase-like activities of proteasomes from subjects with G/G 
genotype were less susceptible to bortezomib. 
 
Abbreviations: granulo, granulocyte; mono, monocyte; WBC, white blood cell 
 


